Please login to the form below

Not currently logged in
Email:
Password:

Sanofi appoints Bill Sibold to lead its Genzyme business

He will succeed David Meeker, who is leaving in the firm in June

Sanofi_Genzyme_Bill_SiboldSanofi has appointed Bill Sibold as executive vice president for Sanofi Genzyme in a move that will also see he join the company's executive committee.

Previously head of Sanofi Genzyme’s multiple sclerosis, oncology and immunology organisation, Sibold has experience in leading global therapy launches.

Prior to Sanofi, Sibold has held a number of leadership positions for biopharmaceutical companies such as Biogen, Avanir Pharmaceuticals and Eli Lilly.

Oliver Brandicourt, chief executive officer at Sanofi, said: “With a strong commitment to serving patients, Sanofi Genzyme has evolved from a rare disease company into a preeminent specialty care business, deeply rooted in science.

“I am confident in Bill’s experience and leadership to build on this strong foundation as we chart the next chapter for Sanofi Genzyme, which has become a real growth driver for Sanofi.”

Sibold will succeed David Meeker, who will leave the company at the end of June.

7th April 2017

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Mind+Matter

We are Mind ‘PLUS’ Matter. The ‘plus’ is important to us because we are all about offering more for our...

Latest intelligence

Menopause-thumbnail.png
Breaking the silence: It’s time to talk about the menopause
Using findings from our latest opinion poll, Vicki Newlove outlines why the hidden landscape of menopause may finally be starting to change....
Committing time to making meaningful connections - top 5 tips
Read the second blog of the series looking at key barriers to effective patient engagement in pharma...
News:
Senior Analytics Specialist joins Research Partnership...